Paraflagellar rod proteins administered with alum and IL-12 or recombinant adenovirus expressing IL-12 generates antigen-specific responses and protective immunity in mice against Trypanosoma cruzi.

Abstract:

:Successful vaccination of mice against an otherwise lethal challenge with the Peru strain of Trypanosoma cruzi necessitates the induction of a strong cell mediated immune response. Previously, immunization of mice with the paraflagellar rod proteins from Trypanosoma cruzi90% reduction in parasitemia in immunized mice challenged with the bloodstream stage of Trypanosoma cruzi.

journal_name

Vaccine

journal_title

Vaccine

authors

Wrightsman RA,Manning JE

doi

10.1016/s0264-410x(99)00380-1

subject

Has Abstract

pub_date

2000-01-31 00:00:00

pages

1419-27

issue

14

eissn

0264-410X

issn

1873-2518

pii

S0264410X99003801

journal_volume

18

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Adjuvant and immunogenic activities of the 73kDa N-terminal alpha-domain of BrkA autotransporter and Cpn60/60kDa chaperonin of Bordetella pertussis.

    abstract::A soluble fraction obtained from Bordetella pertussis was evaluated as adjuvant for the pertussis component of the Diphtheria-Pertussis-Tetanus (DPT) vaccine. High levels of antibodies were induced, and a 78% protection rate of mice challenged with live B. pertussis was observed. Two proteins were identified as the 73...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.08.033

    authors: Cainelli Gebara VC,Risoléo L,Lopes AP,Ferreira VR,Quintilio W,Lépine F,Silva WD,Raw I

    更新日期:2007-01-08 00:00:00

  • Hepatitis C virus soluble E2 in combination with QuilA and CpG ODN induces neutralizing antibodies in mice.

    abstract::Several studies have emphasized the importance of an early, highly neutralizing antibody response in the clearance of Hepatitis C virus (HCV) infection. The envelope glycoprotein E2 is a major target for HCV neutralizing antibodies. Here, we compared antibody responses in mice immunized with native soluble E2 (sE2) fr...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.02.009

    authors: Naarding MA,Falkowska E,Xiao H,Dragic T

    更新日期:2011-04-05 00:00:00

  • HIV subtypes and recombination strains--strategies for induction of immune responses in man.

    abstract::Clinical and experimental studies of HIV-1 subcomponents were made in order to increase their immunogenicity. HIV subtype envelopes A, B and C have been compared and a detailed analysis made by peptides of the coreceptor-ligand interactions. We identified a direct interaction between HIV-1 envelope and a cellular rece...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/s0264-410x(02)00084-1

    authors: Wahren B,Ljungberg K,Rollman E,Levi M,Zuber B,Kjerrström Zuber A,Hinkula J,Leandersson AC,Calarota S,Hejdeman B,Bratt G,Sandström E

    更新日期:2002-05-06 00:00:00

  • Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets.

    abstract::Severe acute respiratory syndrome (SARS) caused by a newly identified coronavirus (SARS-CoV) remains a threat to cause epidemics as evidenced by recent sporadic cases in China. In this communication, we evaluated the efficacy and safety of two SARS vaccine candidates based on the recombinant modified vaccinia Ankara (...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.01.033

    authors: Czub M,Weingartl H,Czub S,He R,Cao J

    更新日期:2005-03-18 00:00:00

  • Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.

    abstract:BACKGROUND:To evaluate the immunological impact of the 23-valent pneumococcal polysaccharide vaccine (23vPPS) at 12 months, for children who have received zero to three infant doses of seven-valent pneumococcal conjugate vaccine (PCV), on responses to a subsequent exposure to a small dose of 23vPPS (mPPS). METHODS:Fiv...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2010.02.087

    authors: Russell FM,Carapetis JR,Balloch A,Licciardi PV,Jenney AW,Tikoduadua L,Waqatakirewa L,Pryor J,Nelson J,Byrnes GB,Cheung YB,Tang ML,Mulholland EK

    更新日期:2010-04-26 00:00:00

  • Expression kinetics of the interleukin-2/immunoglobulin (IL-2/Ig) plasmid cytokine adjuvant.

    abstract::The development of strategies to augment the immunogenicity of plasmid DNA vaccines is critical for improving their clinical utility. One such strategy involves the coadministration of plasmid cytokine adjuvants with DNA vaccines. Although a large number of plasmid cytokines have shown promise as adjuvants in preclini...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.01.065

    authors: Barouch DH,Truitt DM,Letvin NL

    更新日期:2004-08-13 00:00:00

  • Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen.

    abstract::As a step in the development of an oral vaccine against ETEC, we evaluated the safety and immunogenicity of CS6, a polymeric protein commonly found on the surface of ETEC. Formulations included 1 and 5mg doses of CS6, either encapsulated in biodegradable polymer poly(D, L)-lactide-co-glycolide (PLG), or as free protei...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0264-410x(02)00613-8

    authors: Katz DE,DeLorimier AJ,Wolf MK,Hall ER,Cassels FJ,van Hamont JE,Newcomer RL,Davachi MA,Taylor DN,McQueen CE

    更新日期:2003-01-17 00:00:00

  • Directed selection of amino acid changes in the influenza hemagglutinin and neuraminidase affecting protein antigenicity.

    abstract::Influenza virus hemagglutinin (HA) and neuraminidase (NA) proteins elicit protective antibody responses and therefore, are used as targets for vaccination, especially the HA protein. However, these proteins are subject to antigenic drift, decreasing vaccine efficacy, and few to no studies have analyzed antigenic varia...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.09.005

    authors: DeDiego ML,Chiem K,Topham DJ

    更新日期:2018-10-15 00:00:00

  • An immunogenicity study of a newly introduced purified Vero cell rabies vaccine (Abhayrab) manufactured in India.

    abstract::Purified Vero cell culture rabies vaccine "Abhayrab" manufactured by Human Biologicals Institute, Ooty, India was subjected for immunogenicity studies. Pre-exposure study was undertaken on 60 healthy volunteers (Group I) with vaccination on days 0, 7 and 21. A group of 75 patients of category II (Group II), 67 of cate...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.08.001

    authors: Sampath G,Reddy SV,Rao ML,Rao YU,Palaniappan C

    更新日期:2005-01-04 00:00:00

  • Immunogenicity of chi4127 phoP- Salmonella enterica serovar Typhimurium in dogs.

    abstract::Salmonellae are commonly isolated from dogs. The number of dogs infected with Salmonella spp. is surprisingly high and greater than the incidence of clinical disease would suggest. Salmonellosis is common in greyhound kennels. Morbidity can approach 100% in puppies and the mortality ranges to nearly 40%. To date, ther...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(01)00516-3

    authors: McVey DS,Chengappa MM,Mosier DE,Stone GG,Oberst RD,Sylte MJ,Gabbert NM,Kelly-Aehle SM,Curtiss R

    更新日期:2002-02-22 00:00:00

  • Protection against establishment of latent infections in mice immunized with a non-pathogenic herpes simplex virus mutant and reinfected with the pathogenic parental strain.

    abstract::Immunization of hairless mice with a TK-, ACVr, non-pathogenic herpes simplex virus (HSV) type 1 mutant protected the mice against reinfection with lethal doses of the parental pathogenic HSV strain. The protection conferred by the mutant against the establishment of latency after reinfection with the parental strain ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(84)90089-6

    authors: Klein RJ,Kaley LA,Friedman-Kien AE

    更新日期:1984-09-01 00:00:00

  • Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.

    abstract::The development of live attenuated vaccines, allowing for the safe and effective immunisation at mucosal surfaces, is a strategy of great interest for vaccinologists. The main advantage of this approach over conventional parenteral vaccines is the induction of strong mucosal immune responses, allowing targeting of the...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2003.12.033

    authors: Viret JF,Dietrich G,Favre D

    更新日期:2004-06-23 00:00:00

  • Influenza and pertussis vaccination in pregnancy: Portrayal in online media articles and perceptions of pregnant women and healthcare professionals.

    abstract:INTRODUCTION:Online media may influence women's decision to undergo vaccination during pregnancy. The aims of this mixed-methods study were to: (1) examine the portrayal of maternal vaccination in online media and (2) establish the perceived target of vaccine protection as viewed by pregnant women and maternity healthc...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.10.092

    authors: Wilcox CR,Bottrell K,Paterson P,Schulz WS,Vandrevala T,Larson HJ,Jones CE

    更新日期:2018-11-29 00:00:00

  • Estimating the vaccine-preventable burden of hospitalized pneumonia among young Mozambican children.

    abstract::Polysaccharide-protein conjugate vaccines against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae have proven efficacy against radiologically confirmed pneumonia. Measurement of pneumonia incidence provides a platform to estimate of the vaccine-preventable burden. Over 24 months, we conducted surveill...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.03.060

    authors: Roca A,Sigaúque B,Quintó L,Morais L,Berenguera A,Corachan M,Ribó JL,Naniche D,Bassat Q,Sacoor Ch,Nhalungo D,Macete E,Schuchat A,Soriano-Gabarró M,Flannery B,Alonso PL

    更新日期:2010-07-05 00:00:00

  • Lack of immune interference between inactivated polio vaccine and inactivated rotavirus vaccine co-administered by intramuscular injection in two animal species.

    abstract::A parenteral inactivated rotavirus vaccine (IRV) in development could address three problems with current live oral rotavirus vaccines (ORV): their lower efficacy in low and middle-income countries (LMICs), lingering concerns about their association with intussusception, and their requirement for a separate supply cha...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.12.043

    authors: Wang Y,Zade J,Moon SS,Weldon W,Pisal SS,Glass RI,Dhere RM,Jiang B

    更新日期:2019-01-29 00:00:00

  • Development of a Rift Valley fever virus viremia challenge model in sheep and goats.

    abstract::Rift Valley fever virus (RVFV), a member of the family Bunyaviridae, causes severe to fatal disease in newborn ruminants, as well as abortions in pregnant animals; both preventable by vaccination. Availability of a challenge model is a pre-requisite for vaccine efficacy trials. Several modes of inoculation with RVFV Z...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.02.066

    authors: Weingartl HM,Miller M,Nfon C,Wilson WC

    更新日期:2014-04-25 00:00:00

  • Development and validation of a quantitative competitive ELISA for potency testing of equine anti rabies sera with other potential use.

    abstract::In case of a bite by a rabies infected animal, the World Health Organisation recommends a prophylactic treatment including the administration of Human Rabies Immunoglobulins (HRIGs) or highly purified F(ab')2 fragments produced from Equine Rabies Immunoglobulin (F(ab')2 - ERIGs). According to international regulation,...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.04.086

    authors: Korimbocus J,Dehay N,Tordo N,Cano F,Morgeaux S

    更新日期:2016-06-14 00:00:00

  • Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells.

    abstract::We compared the effects of yeast-treated human dendritic cells (DCs) with CD40L-matured human DCs for the induction of effector cells and the number and functionality of CD4(+)CD25(+)CD127(-)FoxP3(+) regulatory T cells (Tregs). DCs were treated with yeast or CD40L and cocultured with isolated autologous CD4(+) T cells...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.04.101

    authors: Cereda V,Vergati M,Huen NY,di Bari MG,Jochems C,Intrivici C,Gulley JL,Apelian D,Schlom J,Tsang KY

    更新日期:2011-07-12 00:00:00

  • Selectively willing and conditionally able: HIV vaccine trial participation among women at "high risk" of HIV infection.

    abstract::Efficacy studies of investigational HIV vaccines require enrollment of individuals at 'high risk' for HIV. This paper examines participation in HIV vaccine trials among women at 'high risk' for HIV acquisition. In-depth interviews were conducted with 17 African-American women who use crack cocaine and/or exchange sex ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.06.064

    authors: Voytek CD,Jones KT,Metzger DS

    更新日期:2011-08-18 00:00:00

  • Improving adolescent HPV vaccination in a randomized controlled cluster trial using the 4 Pillars™ practice Transformation Program.

    abstract:OBJECTIVE:Uptake of meningococcal vaccine (MCV) and tetanus, diphtheria and pertussis (Tdap) vaccine among adolescents has approached Healthy People 2020 goals, but human papillomavirus (HPV) vaccination has not. This study evaluated an intervention using the 4 Pillars™ Practice Transformation Program to increase HPV, ...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2016.11.018

    authors: Zimmerman RK,Moehling KK,Lin CJ,Zhang S,Raviotta JM,Reis EC,Humiston SG,Nowalk MP

    更新日期:2017-01-03 00:00:00

  • Design and immunogenicity analysis of the combined vaccine against zoonotic hepatitis E and foot-and-mouth disease.

    abstract:AIM:Design and immunogenicity assessment of the combined vaccine candidate against zoonotic hepatitis E virus (HEV) and foot-and-mouth disease virus (FMDV). METHODS:Using the molecular cloning technology, we produced and purified 9 HEV ORF2-truncated proteins (HEV genotype 4). Then, we compared their thermal stability...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.09.036

    authors: Liu Z,Behloul N,Baha S,Wei W,Shi R,Meng J

    更新日期:2019-10-31 00:00:00

  • Foot-and-mouth disease vaccine potency testing in cattle using homologous and heterologous challenge strains: precision of the "Protection against Podal Generalisation" test.

    abstract::The level of protection conferred by foot-and-mouth disease (FMD) vaccines in primovaccinated animals primarily depends on the potency of the vaccine and the relatedness of the vaccine strain and circulating field isolate. The "Gold Standard" FMD vaccine potency test is the in vivo test performed in the target species...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.04.034

    authors: Goris N,Maradei E,D'Aloia R,Fondevila N,Mattion N,Perez A,Smitsaart E,Nauwynck HJ,La Torre J,Palma E,De Clercq K

    更新日期:2008-06-25 00:00:00

  • Real world TB vaccines: clinical trials in TB-endemic regions.

    abstract::The first 4 years of the 21st century have been an exciting time for tuberculosis (TB) research. After more than a half-century, the first new vaccines for TB are beginning to enter human clinical trials. Based on advances in proteomics and genomics, new vaccine candidates are filling the preclinical pipeline and our ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2005.01.060

    authors: Doherty TM

    更新日期:2005-03-18 00:00:00

  • Peptide-binding assays and HLA II transgenic Abeta degrees mice are consistent and complementary tools for identifying HLA II-restricted peptides.

    abstract::The identification of MHC class II-restricted peptides has become a priority for the development of peptide-based prophylactic and therapeutic vaccines. The aim of this study was to assess the correlations between peptide-binding assays on purified HLA II molecules and immunization of human HLA II transgenic mice defi...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.11.048

    authors: Depil S,Angyalosi G,Moralès O,Delacre M,Delhem N,François V,Georges B,Hammer J,Maillère B,Auriault C,Pancré V

    更新日期:2006-03-20 00:00:00

  • Efficacy of immunotherapy using antigens of Pythium insidiosum in the treatment of vascular pythiosis in humans.

    abstract::Human pythiosis is an emerging disease in the tropical, subtropical and temperate regions of the world. It is caused by the straminipilan, fungus-like, aquatic organism Pythium insidiosum. Pythiosis occurs in localized as well as systemic or vascular forms. Most patients with arterial pythiosis usually have underlying...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.03.031

    authors: Wanachiwanawin W,Mendoza L,Visuthisakchai S,Mutsikapan P,Sathapatayavongs B,Chaiprasert A,Suwanagool P,Manuskiatti W,Ruangsetakit C,Ajello L

    更新日期:2004-09-09 00:00:00

  • Molecular characterisation of pneumococcal serotype 16F: Established predominant carriage and otitis media serotype in the 7vPCV era.

    abstract::Young Australian Aboriginal children in remote communities experience very high rates of pneumococcal carriage and otitis media. Prior to introduction of the 7-valent pneumococcal conjugate vaccine (7vPCV, Prevenar), serotype 16F was an important type found in nasal and ear discharge swabs. Since commencement of pneum...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.09.016

    authors: Marsh RL,Smith-Vaughan H,Beissbarth J,Hare K,Kennedy M,Wigger C,Mellon G,Stubbs E,Gadil JR,Pettit A,Mackenzie G,Tipakalippa P,Morris PS,Leach AJ

    更新日期:2007-03-22 00:00:00

  • Antibodies against Haemophilus influenzae type b in The Gambia: investigating the extent of protection across age groups.

    abstract::Following a landmark clinical trial, the vaccine against Haemophilus influenzae type b (Hib) was introduced in The Gambia in 1997. Whilst the immunogenicity of this vaccine is well established subsequent to the doses administered under the EPI schedule, little data exists assessing longevity of protection, using serol...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.06.078

    authors: Idoko OT,Roberts E,Cox M,Jafali J,Njie-Jobe J,Mackenzie G,Ota MO,Kampmann B

    更新日期:2014-08-06 00:00:00

  • DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice.

    abstract::Immunization protocols based on priming with plasmid DNA and boosting with recombinants of vaccinia virus (rVV) encoding the same antigen offer great promise for the prevention and treatment of many parasitic and viral infections for which conventional vaccination has little or no effect. To overcome some of the poten...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(02)00450-4

    authors: López-Fuertes L,Pérez-Jiménez E,Vila-Coro AJ,Sack F,Moreno S,Konig SA,Junghans C,Wittig B,Timón M,Esteban M

    更新日期:2002-12-13 00:00:00

  • Specific memory B cell response and participation of CD4+ central and effector memory T cells in mice immunized with liposome encapsulated recombinant NE protein based Hepatitis E vaccine candidate.

    abstract:BACKGROUND:Liposome encapsulated neutralizing epitope protein of Hepatitis E virus (HEV), rNEp, our Hepatitis E vaccine candidate, was shown to be immunogenic and safe in pregnant and non-pregnant mice and yielded sterilizing immunity in rhesus monkeys. METHODS:The current study in Balb/c mice assessed the levels and ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.10.046

    authors: Kulkarni SP,Thanapati S,Arankalle VA,Tripathy AS

    更新日期:2016-11-21 00:00:00

  • Keep calm and carry on vaccinating: Is anti-vaccination sentiment contributing to declining vaccine coverage in England?

    abstract:BACKGROUND:In England, coverage for childhood vaccines have decreased since 2012/13 in the context of an increasingly visible anti-vaccination discourse. We determined whether anti-vaccination sentiment is the likely cause of this decline in coverage. METHODS:Descriptive study triangulating a range of data sources (va...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.05.082

    authors: Edelstein M,Müller M,Ladhani S,Yarwood J,Salathé M,Ramsay M

    更新日期:2020-07-14 00:00:00